Skip to main
ANGO

AngioDynamics (ANGO) Stock Forecast & Price Target

AngioDynamics (ANGO) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

AngioDynamics Inc. is experiencing substantial growth in its Auryon product line, which is successfully expanding its customer base in both the Office-Based Lab (OBL) and hospital settings, positively impacting average selling prices (ASP). The company's focus on improving gross margins through manufacturing initiatives, projected to complete by January 2026, is expected to enhance profitability, supported by a favorable revenue mix with higher contributions from its Med-Tech segment. Management's confidence in sustained growth driven by increasing customer acquisition, utilization in existing accounts, and effective pricing strategies further bolsters the positive outlook for the company's financial performance.

Bears say

AngioDynamics Inc is facing significant challenges due to anticipated tariff headwinds amounting to $4 million to $6 million, which could impact its revenue projections. Additionally, the company expects to encounter pressures on its inventory in the second half of 2026 due to rising raw material costs, further complicating its cost structure. Furthermore, despite recent growth in capital sales, which are indicative of future demand for disposables, the strong performance of NanoKnife disposables in the first quarter of 2026 raises concerns about sustainability in the broader context of financial pressures.

AngioDynamics (ANGO) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of AngioDynamics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About AngioDynamics (ANGO) Forecast

Analysts have given AngioDynamics (ANGO) a Strong Buy based on their latest research and market trends.

According to 3 analysts, AngioDynamics (ANGO) has a Strong Buy consensus rating as of Feb 7, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $19.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $19.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

AngioDynamics (ANGO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.